Summary We evaluated the protective ability of amifostine on peripheral blood mononuclear cell (PBMC)-derived colony-forming unit (CFU) and PB CD34+ cells which were previously exposed in vitro to etoposide, carboplatin, doxorubicin and taxotere. Amifostine pretreatment protected PBMC-derived CFU from the toxic effect of etoposide, carboplatin and taxotere. A significant detrmental effect was exerted by amifostine on the growth of doxorubicin-treated PBMC-derived CFU. Liquid cultures of PB CD34+ cells reproduced faithfully the effects observed on growth of PBMC-derived CFU and confirmed amifostine chemoprotection against etoposide and carboplatin with its detrimental effect on doxorubicin-treated progenitors. Combining the data of viable cell count, cytometric estimation of apoptosis. cell cycle and viable cell replication rate, we found that amifostine protects from etoposide and carboplatin toxicity mainly through a mechanism of cell rescue.
haematological and non-haematological toxicity of cyclophosphamide. carboplatin or cisplatin and cyclophosphamide (Gloxer et al. 1986 : Betticher et al. 1995 : Kemp et al. 1996 . At present. only few data are axailable on the capabilitv of amifostine in prex enting in vitro toxic effects induced in normal human progenitors by chemotherapeutic agents different from alkylating agents (List et al. 1996) . In the present study. we exaluated the chemoprotective effect of amifostine on unfractionated and purified CD34+ haematopoietic progenitors exposed to carboplatin. etoposide. doxorubicin and taxotere.
MATERIALS AND METHODS
Peripheral blood progenitor cell (PBPC) collection and isolation of PB mononuclear cell (PBMC) and PB CD34+ cells Patients with hiah-risk breast and oxarian neoplasms. prexviously untreated with chemotherapy or radiotherapy. w-ere treated w-ith a prexviously described cxtoreductix e/mobilizine regimen and recombinant human granulocyte colony-stimulating factor (rhG-CSF: Filgrastim) at the dose of 5 jcg kL-for 14 days following chemotherapy (Menichella et al. 1994) . Leukaphereses Awere started w-hen the PB CD34+ cell count exceeded the threshold xalue of 20 x 1W 1-1 and performed using an automated blood cell separator as prex iously described (Pierelli et al. 1993 . Aliquots of leukapheresis products were subjected to gradient cell separation using centrifucation (400g for 30 mn at 21'C) and a Ficoll-Paque gradient (1.077 ml-'. Pharmacia LKB. Uppsala. Swxeden). PBMC xxere collected and xxashed tu-ice wxith Ca>+/Mu'-free phosphate-buffered saline supplemented with 1%c human albumin (PBSha). Aliquots of PBMC collected under mobilizing conditions wxere used as a parallel source of purified PB CD34+ cells using a prexiouslI described isolation method (Pierelli et al. 1997 (Ferlini et al. 1995) . DNA analysis was performed bv acquiring up to 15 000 events usinc an EPICS XL flow cvtometer (Coulter) and a doublet exclusion gate so that the analysis was performed only on single nuclei. For the flow cvtometric assessment of apoptosis. cell nuclei w ith a hypodiploid DNA content were quantified following a prexiouslv described procedure (Darzynkiewicz et al. 1997 ).
P-glycoprotein (Pgp)-related transport of doxorubicin
Immunoselected CD34+ cells were incubated in the presence or the absence of amifostine as described in Materials and methods.
loaded with 0.1. 0.25 and 1 jg ml-' doxorubicin at 37°C for 4 h.
w ashed and then analy-sed by flow cvtometrx. as described prexiouslv (De Vincenzo et al. 1996) . Controls included normal peripheral blood l1mphoc%tes incubated xxwith amifostine and/or (Figure 1 ). Figure 1 shows that amifostine pretreatment at 30 jig ml-' produced a significant chemoprotection in etoposidecarboplatin-. and taxotere-treated CFIJ. Chemoprotection from etoposide appeared to be more evident and statistically significant at the lowest etoposide doses (1 and 2 igo ml-'). whereas amifostine was more active with high dosages of carboplatin and taxotere (8 and 20 jgc ml-' and 250 nst respectively). Conversely. amifostine pretreatment did not produce any protectise effect on doxorubicin-exposed cloning progenitors at all doses tested (Figure 1f . In fact. amifostine produced a consistent potentiation of doxorubicin cvtotoxicitv on treated CFU. hich produced a significant decrease of CFU growth at doxorubicin doses of 0.25 jgc ml-' and 1 ml- (Figure 1 ).
Amifostine chemoprotection of PB CD34+ cell cultures in liquid medium
Precultured PB CD34+ cells consisted of 3-day cultured PB CD34+ cells in the presence of IL-3. GM-CSF. G-CSF and SCF. Of these cells. 80 ± 6% still expressed the CD34 antigen and 60 ± 5%7 were in GJG1. whereas 40 ± 5 were in S/G,/M phase of the cell cycle on average. These cells were used to assess the amifostine and drug effects on haematopoietic progenitors in liquid culture. The amifostine excipient mannitol did not si2nifi-cantly affect PB CD34+ cell growth and did not exert any chemoprotection on these cells. Amifostine provided a significant chemoprotection for both etoposide-treated (2 jge ml-' ) and carboplatin-treated (4 g l-l') PB CD34-cells in liquid culture. abrogating their myelotoxic effect at any time point of culture ( Figure  2 ) in five different consecutive experiments. Conversely. amifostine pretreatment produced a consistent detrimental effect on growth of doxorubicin-treated (0.25 jg^ml-') PB CD34+ cells.
confirming the results observed in PBMC-derived CFU (Figure 2 ). Amifostine did not protect PB CD34+ cells exposed to taxotere using a taxotere dose of 50 nst. which produced a 50% growth inhibition of PB CD34+ cells. Taxotere doses higher than 50 n-Mi produced a complete growth inhibition of PB CD34+ cells. Figure   3 shows that at 1 mm the antioxidant compound N-acetylcysteine produced a similar potentiation of the myelotoxic effect of doxoru- studied. suggesting that neither drug exposure nor amifostine pretreatment followed by drugr exposure considerably affected the replication rate of PB CD34+ cells which survived the toxic effect produced by etoposide. carboplatin. doxorubicin and taxotere (data not shown).
Amifostine pretreatment and Pgp-related transport of doxorubicin
Because amifostine potentiated the activity of doxorubicin. we evaluated its potential effect on Pgp activity by flow cytometry. Results indicated that amifostine exerted no significant effect on the Pgp pump efflux activity (Table 1) . CD34+ cells accumulated considerably less doxorubicin than normal lymphocytes. but this capacity was not influenced by amifostine at all doxorubicin concentrations tested.
DISCUSSION
Preclinical studies in mice showed that amifostine pretreatment consistently decreases the toxic effect of radiation. nitrogen mustards. cisplatin. cyclophosphamide. carmustine. melphalan
and 5-fluorouracil on haematopoietic progenitor cells (Wasserman et al. 1981 (1995) demonstrated that amifostine pretreatment protects human bone marrow CFU and lono-term culture-initiating cells (LTC-IC) from mafosfamide or 4-hydroperoxycyclophosphamide (4-HC) treatment. Collectively. these data suggest that amifostine exerts a significant myeloprotective effect from toxicity produced by radiation. 5-fluorouracil and alkylating, agents. These results were confirmed in three clinical studies in which amifostine significantly reduced the haematological toxicity of cyclophosphamide. carboplatin or cisplatin and cyclophosphamide (Glover et al. 1986 : Betticher et al. 1995 : Kemp et al. 1996 . In this study. we tested the effectiveness of amifostine pretreatment in protecting unfractionated and purified human haematopoietic progenitors exposed to carboplatin. etoposide. doxorubicin and taxotere. Unfractionated progenitor cultures in semisolid medium showed that a consistent and significant protective effect is produced by amifostine pretreatment on carboplatin. etoposide and high-dose taxotere (250 n.x. which corresponds to the plasma peak levels achievable in vivo administering 70 m, m-' of drug: Bisset et al. 1993) exposed progenitors. Surprisingly. amifostine pretreatment significantly worsened the myelotoxic effect of doxorubicin.
These results suggest that chemoprotection by amifostine is a drug-dependent process rather than an indefinite optimization of growth of those haematopoietic progenitors which escaped the toxic damage produced by the different agents. Liquid cultures of PB CD34+ cells confirmed that a significant chemoprotection can be produced by amifostine in etoposide-and carboplatin-treated progenitors. The detrimental effect exerted by amifostine on doxorubicin-exposed progenitors was documented also in this model of in vitro progenitor growth. This detrimental effect became evident from the 5th day of liquid culture onward with an evident decline of cell growth compared with doxorubicin alone.
suggaesting that the enhancement of doxorubicin toxicity by amifostine was the result of a progressive inability of cells to adequately proliferate in response to growth factor stimulation during, culture rather than a greater cell killing immediately after drug exposure. Liquid cultures made possible the monitoring of apoptotic events, cycling status and viable cell replication rate (by progressive halving, of a fluorescent dve) during etoposide-. carboplatin-and doxorubicin-exposed PB CD34+ cell growth in -itro after amifostine pretreatment. as well as in controls. The body of these data suggests that in etoposide-and carboplatin-treated progenitors amifostine pretreatment does not considerably affect the number of apoptotic events. the cell distribution into the different phases of the cell cycle and the number of cell div-isions of v-iable cells from day 3 of culture onward. This fact suagests that amifostine produces a specific protection from etoposide and carboplatin toxic effects. increasingr the fraction of cells which survive the cell damage generated by these drugs. Progenitor rescue after drug treatment could be mediated by the previously documented abilitv of amifostine to bind the active species of platinum agents. to reverse platin-DNA adduct formation and to repair DNA by hydrogen atom transfer or oxygen depletion (Purdie and Inhaber. 1983 : Willson et al. 1983 : Treskes and van der Vijgh. 1993 ).
Conversely. in doxorubicin-exposed PB CD34+ progenitors. amifostine pretreatment produces an accumulation of cells in the GJM phase of the cell cycle in the absence of a proportional increase in the viable cell division number. and in the presence of an increased number of dead cells in the cultures. This fact suaaests that amifostine enhances the capacity of doxorubicin to produce cell death through a GJM arrest. which is a well-known dose-dependent cytokinetic effect of anthracyclines (Bartkowiak et al. 1992 ). This study also shows that doxorubicin potentiation by amifostine is not mediated by an increased retention of doxorubicin. a possibility which must be excluded because haematopoietic progenitors are characterized by an active Pgp-mediated efflux system (Chaudhary and Roninson. 1991) . On the whole. these data support the hypothesis that the potentiation of doxorubicin haematopoietic toxicity by amifostine in vitro could lie in the increased intracellular availability of free exogenous thiols which are known to catalyse the generation of hydrogen peroxide and hydroxyl radicals in the presence of a doxorubicin-iron complex (Muindi et al. 1985) . or alternatively in the reported capacity of amifostine to reduce intracellular glutathione levels Nagaele. 1989: Meier and Issels. 1995) . Using liquid cultures of PB CD34+ cells. we found that pretreatment with N-acetylcysteine produces an increase of the toxic effect of doxorubicin as well as amifostine does. The antioxidant nature of both compounds confirms that the detrimental effect on cell growth is probably due to a greater intracellular availability of exogenous antioxidant compounds. Therefore. our data suggest caution in the combined use of amifostine and doxorubicin until their pharmacological interaction can be fully clarified. Preliminary data from our laboratory indicate that amifostine does not worsen the myelotoxic effect of epirubicin. daunorubicin and mitoxantrone on purified PB CD34+ cells. and these preliminary findings are in harmony with the observations made by List et al (1996) . Finally. our in vitro data on amifostine haematoprotection after treatments with etoposide. carboplatin and taxotere and the previously reported works on the chemoprotection of normal tissue after treatment with several chemotherapeutic agents encourage the clinical use of amifostine in preventinc toxicity of anticancer therapy.
